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In an effort to identify and characterize precursors of gastrin 
in tissues, we generated region-specific antisera against a 
synthetic progastrin peptide, Tyr-Gly-Trp-Met-Asp-Phe-Gly-Arg-Arg 
(GL9), as deduced from the nucleotide sequence of gastrin mRNA. 
This antisera did not cross-react with gastrin or progastrin 
peptides with shorter carboxyl-terminal extensions. Progastrin-like 
imnunoreactivity (PGLI) was measured in porcine antrum at a 
concentration of 6.8 f  1.2 pmol/g wet weight (mean f  SE, n = 5), or 
roughly 0.2% of that of gastrin. On Sephadex 650 chromatography, a 
major peak of PGLI was eluted as a slightly larger molecule than 
gastrin heptadecapeptide (617) but possessed the same N-terminal 
imnunoreactivity. These findings suggest that 617 may be formed by 
processing of a carboxyl-terminally extended precursor as an 
alternative to cleavage of big gastrin (634). 0 1985 Academic press, kc. 
Gastrin has a variety of physiological actions in the gut, the 
most important of which appears to be stimulation of acid secretion 
(1). Recently the structure of progastrin has been deduced from the 
nucleotide sequence of mRNA cloned from hog antrum and human 
Zollinger-Ellison tumors (2,3), however, no direct evidence is 
available for the existence of progastrin in tissues. Thus, we 
developed antisera that recognize the proposed progastrin sequence 
specifically at the site where the processing step for creating the 
biologically important carboxyl-terminal amide must take place. 
With this antisera, we identified and characterized progastrin-like 
imnuonoreactivity (PGLI) in porcine stomach. The biochemical 
characteristics ofPGL1 provide insight into the mechanism of 
gastrin biosynthesis. 
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MATERIALS AND METHODS 
Peptides: The peptides with specific progastrin sequences utilized 
in this study are indicated on Table 1. GL7, GLg, and GLll were 
custom-synthesized by Peninsula Laboratories (Belmont, CA). GL8 was 
prepared from GLll by tryptic digestion and Asp-Phe-Gly-Arg-Arg was 
made from GL9 by CNBr cleavage. 617 (human) and Arg-Arg were 
obtained from Research Plus (Bayonne, NJ) and 634 and hexagastrin 
(66) were kindly provided by Dr. John Walsh (Los Angeles, CA). Gl- 
13 (human) was a product of Bachem (Torrance, CA). Dynorphin A l-7 
(porcine), human adrenocorticotropic hormone (ACTH l-24), 
neurotensin 1-13, and bombesin were purchased from Peninsula 
Laboratories. Porcine pancreatic glucagon was obtained from Eli 
Lilly (Indianapolis, IN). Cholecystokinin octapeptide (CCK8) and 
desamido CCK8 were provided by Dr. Travis Solomon (Columbia, MO). 
Sanatostatin 14 was supplied by Diamalt (Munich, West Germany). 
Tissue Extraction: Small pieces of fresh porcine gastric tissue (l- 
29) were boiled for 10 min in distilled water (10 ml/g wet weight) 
and then homogenized with a Polytron tissue homogenizer. Tissue 
homogenates were ultracentrifuged at 100,000 x g for 30 min, and the 
supernatant was stored at -20° until further analysis. 
Antibody Generation: GL9 was conjugated to bovine serum albumin 
using glutaraldehyde with a molar ratio of peptide to protein of 10 
to 1. GL9-protein conjugate was emulsified with Freunds complete 
adjuvant (Difco, Detroit, MI) and administered subcutaneously to New 
Zealand white rabbits. 
monthly intervals. 
Identical booster injections were given in 
Radioimnunoassay: GL9 was labeled with 1251 using the standard 
chloramine T method (4). The label was purified by chromatography 
on a Sephadex G-10 (Pharmacia, Picataway, NJ) column (1.0 x 20 cm) 
equilibrated with O.lM amnonium acetate pH 5.0/O-l% 8SA followed by 
chromatography on a CM-cellulose (CM-52, Whatman, Kent, U.K.) column 
(1.5 x 10 cm) equilibrated with the same buffer and eluted with a 
~2:~~m~:t"~~~:tc~rt~~~~iY15acetate (O:l M to 1.0 M). Standard 
I-GL9, various amounts of standard 
peptide or unknown sample and antibody (Ab 8207, final dilution of 1 
to 50,000) in 1 ml of sodium barbital buffer pH 8.6 containing 0.1% 
BSA, 2mM EDTA and 0.02% NaN 
4OC, free and bound radioac 9: 
After incubation for 18-20 hrs at 
coated charcoal. 
ivity were separated using dextran- 
Amino-terminal 617 assays using antibody 1295 and 
carboxyl-terminal gastrin radioimnunoassay using antibodies 5135 and 
1611 were performed using methods previously described (5,6). These 
gastrin antibodies were kindly supplied by Dr. John Walsh. 
TABLE 1 
STRUCTURE OF GASTRIN, PROGASTRIN AND SYNTHETIC PROGASTRIN PEPTIOES 
---Tyr-Gly-Trp-Met-Gly-Phe-Gly-Arg-Arg-Ser-Ala-Gly--- Progastrin 
Tyr-Gly-Trp-Met-Asp-Phe-Gly-Arg-Arg-Ser-Ala GLll 
Tyr-Gly-Trp-Met-Asp-Phe-Gly-Arg-Arg GL 9 
Tyr-Gly-Trp-Met-Asp-Phe-Gly-Arg GL 8 
Tyr-Gly-Trp-Met-Asp-Phe-Gly GL 7 
---Tyr-Gly-Trp-Met-Asp-Phe-NH2 Gastrin 
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Affinity Chromatography: Purified gamma globulin (120 mg) from 
antisera 8207 was coupled to Affi-Gel 10 (Bio-Rad Laboratories, 
Richmond, CA) according to methods described in the manufacturer's 
bulletin (Technical Bulletin 1085). The affinity beads adsorbed 
both GL9 and GLll but completely excluded GL7, 617 and G 1-13. 
Recovery of PGLI on affinity chromatography ranged from 85-100X. 
Gel-Filtration Column Chromatography: Affinity purified materials 
were lyophilized, reconstituted in 0.2 M Tris-HCl pH 8.0 containing 
2 mM EDTA, and applied to a Sephadex G-50 (superfine) column (1.5 x 
75 cm) equilibrated and eluted in sodium barbital buffer pH 8.6 
containing 2 mM EDTA. The column was calibrated with blue dextran, 
634 (human), 617 and the salt elution peak. 
RESULTS AND DISCUSSION 
Competitive binding curves for radioimnunoassay with Ab 8207 
using 1251-GL9 as label are shown in Fig. 1. The carboxyl terminal 
Arg-Arg structure appeared to be critically important for binding to 
this antibody. Loss of one arginine residue at the carboxyl 
terminus of GL9 (i.e. GL8) decreased binding to 0.1% and virtually 
no binding was observed with GL7 which lacks both arginines. 
However, other amino acids in the structure of GL9 were also 
necessary for binding because neither the dipeptide Arg-Arg nor 
peptides containing Arg-Arg at the carboxyl terminus or elsewhere in 
their sequence (neurotensin, ACTH, glucagon or dynorphin A l-7), 
1 10 102 103 104 106 106 
Peptlde concentration hxWml) 
Y  OO- 
~l~ib~a,_~~~~t~~~v~r~~n~~~g curves for antibody 8207. The ratio of 
I-GL9 (B/F) are expressed as a percentage 
of maximal B/F. Fifty percent inhibition of tracer binding to 
antibody occurred at a concentration of 41 f  4 fmol/ml (mean f  SE, 
n = 5) of GL9. The intra-assay coefficients of variation for 
samples containing 10, 50, and 125 fmol/ml of GL9 were 11.6, 2.4, 
and 6.6% (n = 5), respectively. The inter-assay coefficients of 
variations for these same samples were 18.0, 3.4, and 3.7% (when 
measured in 4 consecutive assays). 
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cross-reacted with the antibody. The antibody cross-reacted 3-5% 
with Asp-Phe-Gly-Arg-Arg but the label displacement curve with this 
peptide was not parallel to the one obtained with GL9. Extension at 
the C-terminus by two more amino acids (GLll) diminished binding but 
the degree of cross-reactivity was much greater than that observed 
with GL7 or GL8. Other peptides including amidated forms of gastrin 
(634, 617, G6), the amino terminal tri-decapeptide of 617 (Gl-13), 
CCK8, desamido CCK8 (CCK 8-OH), somatostatin and bombesin all failed 
to cross-react with our antibody at the highest concentration tested 
(1 nmol/ml). From our detailed specificity studies it is evident 
that the antigenic requirement for recognition involves a portion of 
the carboxyl terminal sequence of gastrin as well as an extension of 
at least three amino acids as predicted from the nucleotide sequence 
of gastrin mRNA. Therefore, we termed material imnunoassayable with 
our antibody as progastrin-like immunoreactivity (PGLI). 
In support of this assumption, PGLI was demonstrated almost 
exclusively in the antral mucosa, matching the distribution of 
gastrin (Table 2). Furthermore, our preliminary itnnunohistochemical 
studies showed that PGLI was localized specifically to antral G- 
cells (7). The level of PGLI, however, was much lower than that of 
gastrin, comprising only 0.2% of total gastrin inunoreactivity. 
Dilutions of PGLI in antral extracts displaced 1251-GL9 bound to our 
TABLE 2 
GASTRIN AND PROGASTRIN-LIKE IMMlJNOREACTIVITY (PGLI) 
CONCENTRATIONS IN PORCINE STOMACH 
PGLI GASTRIN 
TISSUE (Ab 8207) (Ab 5135) 
Cardiac Mucosa 0.4 f  0.1 (3)* 0.7 f  0.1 (3) 
Fundic Mucosa 0.3 f  0.2 (3) 18.5 f  15.6 (3) 
Antral Mucosa 6.8 f  1.2 (5) 2800 f  942 (5) 
Muscle Layer 0.2 f  0.1 (3) 20.9 f  9.4 (3) 
*pmol/g wet weight, mean f  SE, n indicated in parentheses 
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Fig. 2: Chromatography of porcine antral extracts on progastrin 
affinity beads. Boiling water extracts of porcine antral mucosa 
were applied to Affi-Gel 10 beads linked to antibody 8207. The 
column was washed with 3 column volumes of phosphate buffer (A) 
followed by atnnonium acetate buffer (B) and eluted with 2% TFA 
(C). Fractions were radioimnunoassayed with antibodies 8207, 1295 
and 1611 for PGLI, amino-terminal 617 imnunoreactivity and carboxyl- 
terminal gastrin, respectively. 
3: Gel filtration of porcine antral extracts purified by 
hy chromatography. The materials purified by affinity 
chromatography (see Fig. 2) were applied to a Sephadex G-50 
(superfine) column as described in the text. Both amino-terminal 
617 and PGLI activity were measured by radioimnunoassay using 
antibodies 1295 and 8207, respectively. Since all the carboxyl- 
terminal gastrin imnunoreactivity was removed by previous affinity 
chromatography none was detected in the eluted fractions. 
antibody in parallel with the standard curve for radioimnunoassay. 
As depicted in Fig. 2, PGLI was completely adsorbed to an affinity 
column made with antibody 8207 whereas all the gastrin-like 
imnunoreactivity, measured with a carboxyl-terminal specific assay, 
appeared in the column void. In contrast, a substantial fraction of 
amino-terminal G17-like imnunoreactivity was co-eluted with PGLI 
using TFA. These data indicate that some of the PGLI in antral 
extracts has an amino terminal structure imnunochemically similar to 
617. When affinity purified PGLI was applied to Sephadex G-50 
chromatography, a major peak appeared as a slightly larger molecule 
than 617 and possessed amino-terminal G17-like inanunoreactivity 
(Fig. 3), suggesting that its molecular structure consisted of 617 
with a carboxyl-terminal extension in place of the amide moiety. 
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The existence of such a molecule suggests the 617 may be formed from 
this molecule through carboxyl terminal processing, although 
prevailing theories (8, 9) suggest that 617 is solely derived from 
the cleavage of 634. 
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